未登录The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis
Sato, Ryo; Suzuki, Takanori; Matsuura, Kentaro; Kato, Daisuke; Hayashi, Katsumi; Okayama, Kohei; Okumura, Fumihiro; Sobue, Satoshi; Kusakabe, Atsunori; Hasegawa, Izumi; Narita, Kiyoto; Mizoshita, Tsutomu; Kimura, Yoshihide; Kondo, Hiromu; Kojima, Hisayo; Hayashi, Kazuki; Ozasa, Atsushi; Kawamura, Hayato; Fujiwara, Kei; Nojiri, Shunsuke; Kataoka, Hiromi .png)
分享.png)
收藏Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysisdurvalumab联合tremelimumab治疗第二疗程开始时的中性粒细胞与淋巴细胞比率预测晚期肝细胞癌患者的治疗效果: 一项多中心分析Suzuki, Takanori; Matsuura, Kentaro; Sobue, Satoshi; Kato, Daisuke; Hayashi, Katsumi; Kondo, Hiromu; Anbe, Kaiki; Mizoshita, Tsutomu; Okayama, Kohei; Okumura, Fumihiro; Kimura, Yoshihide; Ozasa, Atsushi; Inada, Hiroki; Tokunaga, Takayuki; Narahara, Satoshi; Kawamura, Hayato; Fujiwara, Kei; Nojiri, Shunsuke; Kataoka, Hiromi; Tanaka, Yasuhito 分享 收藏 分享 收藏 Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysisSuzuki, Takanori; Matsuura, Kentaro; Suzuki, Yuta; Okumura, Fumihiro; Nagura, Yoshihito; Sobue, Satoshi; Matoya, Sho; Miyaki, Tomokatsu; Kimura, Yoshihide; Kusakabe, Atsunori; Narahara, Satoshi; Tokunaga, Takayuki; Nagaoka, Katsuya; Murakami, Shuko; Inoue, Takako; Kuroyanagi, Keita; Kawamura, Hayato; Fujiwara, Kei; Nojiri, Shunsuke; Kataoka, Hiromi; Tanaka, Yasuhito 分享 收藏 Kinetics of HBcrAg and HBsAg using highly sensitive iTACT assays in chronic hepatitis B patients with HBsAg seroclearanceSuzuki, Takanori; Matsuura, Kentaro; Watanabe, Takehisa; Matsui, Takeshi; Ogawa, Shintaro; Kawamura, Hayato; Kuno, Kayoko; Fujiwara, Kei; Nojiri, Shunsuke; Kataoka, Hiromi; Tanaka, Yasuhito 分享 收藏 Serum inducible protein 10 kDa/C-X-C motif chemokine 10 levels predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agentssNagura, Yoshihito; Suzuki, Takanori; Matsuura, Kentaro; Ogawa, Shintaro; Kawamura, Hayato; Kuno, Kayoko; Fujiwara, Kei; Nojiri, Shunsuke; Nagaoka, Katsuya; Iio, Etsuko; Watanabe, Takehisa; Kataoka, Hiromi; Tanaka, Yasuhito 分享 收藏 A Phase 2, Prospective, Multicenter, Single-arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-stage Hepatocellular Carcinoma: TACTICS-L TrialKudo, Masatoshi; Ueshima, Kazuomi; Saeki, Issei; Ishikawa, Toru; Inaba, Yoshitaka; Morimoto, Naoki; Aikata, Hiroshi; Tanabe, Nobukazu; Wada, Yoshiyuki; Kondo, Yasuteru; Tsuda, Masahiro; Nakao, Kazuhiko; Ito, Takanori; Hosaka, Tetsuya; Kawamura, Yusuke; Kuzuya, Teiji; Nojiri, Shunsuke; Ogawa, Chikara; Koga, Hironori; Hino, Keisuke; Ikeda, Masafumi; Moriguchi, Michihisa; Hisai, Takashi; Yoshimura, Kenichi; Furuse, Junji; Arai, Yasuaki 分享 收藏 The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysisMatoya, Sho; Suzuki, Takanori; Matsuura, Kentaro; Suzuki, Yuta; Okumura, Fumihiro; Nagura, Yoshihito; Sobue, Satoshi; Kuroyanagi, Keita; Kusakabe, Atsunori; Koguchi, Hiroki; Hasegawa, Izumi; Miyaki, Tomokatsu; Tanaka, Yoshito; Kondo, Hiromu; Kimura, Yoshihide; Ozasa, Atsushi; Kawamura, Hayato; Kuno, Kayoko; Fujiwara, Kei; Nojiri, Shunsuke; Kataoka, Hiromi 分享 收藏 Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivationSuzuki, Takanori; Matsuura, Kentaro; Urakabe, Kenji; Okumura, Fumihiro; Kawamura, Hayato; Sobue, Satoshi; Matoya, Sho; Miyaki, Tomokatsu; Kimura, Yoshihide; Kato, Daisuke; Kusakabe, Atsunori; Tanaka, Yoshito; Ozasa, Atsushi; Nagura, Yoshihito; Fujiwara, Kei; Nojiri, Shunsuke; Hagiwara, Shinya; Kusumoto, Shigeru; Inoue, Takako; Tanaka, Yasuhito; Kataoka, Hiromi 分享 收藏 Efficacy of minocycline hydrochloride aspiration sclerotherapy with additional monoethanolamine oleate aspiration sclerotherapy for symptomatic hepatic cystsKimura, Yoshihide; Fujiwara, Kei; Matsuura, Kentaro; Suzuki, Takanori; Senoo, Kyouji; Tsuchida, Kenji; Mori, Yoshinori; Hirano, Atsuyuki; Nomura, Satoshi; Kitagawa, Mika; Tomita, Yusaku; Kanaiwa, Hiroki; Imazu, Mitsuki; Nagura, Yoshihito; Nojiri, Shunsuke; Kataoka, Hiromi 分享 收藏 分享 收藏 Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarteria Chemoembolization Alone in Patients with Unresectable Hepatocellular CarcinomaKudo, Masatoshi; Ueshima, Kazuomi; Ikeda, Masafumi; Torimura, Takuji; Tanabe, Nobukazu; Aikata, Hiroshi; Izumi, Namiki; Yamasaki, Takahiro; Nojiri, Shunsuke; Hino, Keisuke; Tsumura, Hidetaka; Kuzuya, Teiji; Isoda, Norio; Moriguchi, Michihisa; Aino, Hajime; Ido, Akio; Kawabe, Naoto; Nakao, Kazuhiko; Wada, Yoshiyuki; Ogasawara, Sadahisa; Yoshimura, Kenichi; Okusaka, Takuji; Furuse, Junji; Kokudo, Norihiro; Okita, Kiwamu; Johnson, Philip James; Arai, Yasuaki 分享 收藏 A novel prostaglandin I2 agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice一种新型前列腺素I2激动剂ONO-1301减轻非酒精性脂肪性肝炎模型小鼠的肝脏炎症并抑制纤维化Motegi, Satoko; Tsuchiya, Atsunori; Iwasawa, Takahiro; Sato, Takeki; Kumagai, Masaru; Natsui, Kazuki; Nojiri, Shunsuke; Ogawa, Masahiro; Takeuchi, Suguru; Sakai, Yosiki; Miyagawa, Shigeru; Sawa, Yoshiki; Terai, Shuji 分享 收藏 Combination therapy of Juzentaihoto and mesenchymal stem cells attenuates liver damage and regresses fibrosis in miceJuzentaihoto和间充质干细胞联合治疗减轻小鼠肝损伤并消退纤维化Iwasawa, Takahiro; Nojiri, Shunsuke; Tsuchiya, Atsunori; Takeuchi, Suguru; Watanabe, Takayuki; Ogawa, Masahiro; Motegi, Satoko; Sato, Takeki; Kumagai, Masaru; Nakaya, Taiki; Ohbuchi, Katsuya; Nahata, Miwa; Fujitsuka, Naoki; Takamura, Masaaki; Terai, Shuji 分享 收藏 Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in miceNojiri, Shunsuke; Tsuchiya, Atsunori; Natsui, Kazuki; Takeuchi, Suguru; Watanabe, Takayuki; Kojima, Yuichi; Watanabe, Yusuke; Kamimura, Hiroteru; Ogawa, Masahiro; Motegi, Satoko; Iwasawa, Takahiro; Sato, Takeki; Kumagai, Masaru; Ishii, Yui; Kitayama, Tomomi; Li, Yu-Tung; Ouchi, Yuya; Shimbo, Takashi; Takamura, Masaaki; Tamai, Katsuto; Terai, Shuji 分享 收藏 Small extracellular vesicles derived from interferon-γ pre-conditioned mesenchymal stromal cells effectively treat liver fibrosisTakeuchi, Suguru; Tsuchiya, Atsunori; Iwasawa, Takahiro; Nojiri, Shunsuke; Watanabe, Takayuki; Ogawa, Masahiro; Yoshida, Tomoaki; Fujiki, Katsunori; Koui, Yuta; Kido, Taketomo; Yoshioka, Yusuke; Fujita, Mayu; Kikuta, Junichi; Itoh, Tohru; Takamura, Masaaki; Shirahige, Katsuhiko; Ishii, Masaru; Ochiya, Takahiro; Miyajima, Atsushi; Terai, Shuji 分享 收藏 Mesenchymal stem cells cultured under hypoxic conditions had a greater therapeutic effect on mice with liver cirrhosis compared to those cultured under normal oxygen conditionsKojima, Yuichi; Tsuchiya, Atsunori; Ogawa, Masahiro; Nojiri, Shunsuke; Takeuchi, Suguru; Watanabe, Takayuki; Nakajima, Kenji; Hara, Yukio; Yamashita, Junji; Kikuta, Junichi; Takamura, Masaaki; Ishii, Masaru; Terai, Shuji 分享 收藏 分享 收藏 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
HEPATOLOGY RESEARCH.png)
